Abstract
Benzoyl peroxide and clindamycin are commonly used topically for the treatment of acne vulgaris. This article reviews data on a combination gel formulation of benzoyl proxide 2.5% and clindamycin phosphate 1.2%. This formulation is approved in the USA for the treatment of acne vulgaris, and incorporates the active ingredients into a novel vehicle. Multiple clinical studies have established the efficacy and safety profiles of the formulation, with data available on its use in various severity grades of acne vulgaris and in the adolescent population as a subset. Cumulative irritation data and evaluations of epidermal barrier function support a favorable skin tolerability profile. Subject quality of life assessments were also favorable towards this formulation.
Acknowledgements
The author acknowledges the support of Brian Bulley MSc in the development of this manuscript.
Financial & competing interests disclosure
James Q Del Rosso has served as a consultant and speaker for Coria/Valeant, but was not a clinical investigator in the studies evaluating BP 2.5–CP 1.2% gel (Acanya Gel, Coria Laboratories). Del Rosso is a consultant, speaker and clinical researcher for other companies who are affiliated with acne products, including Allergan, Galderma, Intendis, Medicis, Onset Therapeutics, Ortho Dermatologics, Pharmaderm/Nycomed, Ranbaxy, Stiefel/GlaxoSmithKline, Triax and Warner-Chilcott. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.